Systemic Anti Cancer Therapy Including Cytotoxic Agents
Found 5 free book(s)
NHS England » Management extravasation of a systemic anti ...
www.england.nhs.ukMgt of Extravasation of a Systemic Anti-Cancer Therapy including Cytotoxic Agents v1.docx Document Purpose The purpose of this guideline is to provide clear guidance on the causes, prevention, recognition and management of an extravasation of a Systemic Anti-Cancer Therapy used in the treatment of malignant disease in the patient
Systemic Anti-Cancer Therapy (SACT) Competency Passport
www.ukons.orgSystemic Anticancer Therapy refers to all drugs, irrespective of their route of administration, with direct anti-tumour activity, including traditional cytotoxic chemotherapy such as cyclophosphamide, hydroxycarbamide, small molecule/antibody treatments such as imatinib, rituximab, immunotherapies such as nivolumab, ipilimumab
Systemic Anti-Cancer Therapy (SACT) Competency Passport
www.ukons.orgSystemic Anticancer Therapy refers to all drugs, irrespective of their route of administration, with direct anti-tumour activity, including traditional cytotoxic chemotherapy such as cyclophosphamide, hydroxycarbamide, small molecule/antibody treatments such as imatinib, rituximab, immunotherapies such as nivolumab, ipilimumab
NHS England » Systemic anti-cancer treatment management ...
www.england.nhs.ukSystemic Anti-Cancer Therapies (SACT). This guideline has been developed to support the handling, prescribing and administration of SACT agents for adult patients within the West Midlands Network. Note: Please refer to separate individual trust policy for guidance on intrathecal drug administration. 2. INTRODUCTION
SARCOIDOSIS TREATMENT GUIDELINES
www.stopsarcoidosis.orgincluding intravenous corticosteroids and anti-TNF therapy. Its side effects can include nausea, vomiting, anorexia, alopecia, acne, leukopenia, oral ulcers, skin hyperpigmenta-tion and fatigue. Less common but more severe side effects include hemorrhagic cystitis and an …